This segment focuses on the research, development, and clinical trials of allogeneic CAR-T cell therapies for the treatment of blood cancers. Caribou Biosciences utilizes its proprietary chRDNA technology platform to engineer CAR-T cells, which are designed to target and eliminate cancer cells. The lead product candidate, CB-010, is in a Phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma. Other programs, such as CB-011 and CB-012, are in Phase 1 trials for multiple myeloma and acute myeloid leukemia, respectively. The company's competitive advantage lies in its CRISPR genome-editing technology, which enables the creation of off-the-shelf cell therapies. Future opportunities include expanding the pipeline to other cancer types and improving the efficacy and safety of CAR-T cell therapies. Partnerships with companies like AbbVie and Pfizer support the development and commercialization efforts in this segment.